HER2-LOW EDUCATIONAL WEB-PORTAL

This project is sponsored by IQN Path and provided by the UK NEQAS ICC & ISH. The results of the DESTINY-Breast 04 phase-3 clinical trial provided evidence that HER2-Low expressing breast cancer responded to treatment using the antibody-drug conjugate. trastuzumab deruxtecan (T-DXd) therapy [1] . As a result of the trial’s findings, the FDA approved read more…